A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524130-26-00

Enrollment

Registered

2026-08-26

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Cancers

Brief summary

Confirmed Objective Response Rate (ORR) per RECIST v1.1 as assessed by Investigator

Detailed description

Duration of Response (DOR) per RECIST v1.1 as assessed by Investigator, Disease Control Rate (DCR) per RECIST v1.1 as assessed by Investigator, Progression-free Survival (PFS) per RECIST v1.1 as assessed by Investigator, Types and incidence and severity of h Treatment-emergent Adverse Events (TEAEs), PK parameters of Rina-S related analytes

Interventions

DRUGRinatabart Sesutecan

DRUGPEGFILGRASTIM

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Duration of Response (DOR) per RECIST v1.1 as assessed by Investigator, Disease Control Rate (DCR) per RECIST v1.1 as assessed by Investigator, Progression-free Survival (PFS) per RECIST v1.1 as assessed by Investigator, Types and incidence and severity of h Treatment-emergent Adverse Events (TEAEs), PK parameters of Rina-S related analytes	—

Primary

Measure	Time frame
Confirmed Objective Response Rate (ORR) per RECIST v1.1 as assessed by Investigator	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 28, 2026